The ASX healthcare share's price has softened recently, but the long-term investment case remains firmly intact for patient ...

With the ASX 200 near 8,700 points, ResMed Inc. (ASX: RMD) still looks like a quality blue chip stock worth considering.

Resmed Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for sma ...

Choosing the right CPAP mask can make or break your sleep therapy success. From cushion materials to strap adjustments, small details change comfort and adherence. New designs and clever hacks are ...

ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a ...

Article Page URL has been copied to clipboard for sharing. Mentioned: ResMed Inc Chess Depository Interest (RMD) ResMed’s fourth-quarter fiscal 2025 underlying EBIT grew 7% on the third, driven by ...

ResMed Inc (RMD) reports an 11% revenue increase and strategic acquisition plans, while navigating supply chain challenges and competitive pressures.

Q3 reiterated FY 2026 gross margin range “62% to 63%” (CFO Sandercock), consistent with Q2’s updated FY 2026 gross margin range.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing ...